Familial forms of Alzheimer disease are caused by mutations in APP or in the PSEN1 and PSEN2 genes. All these mutations affect the generation of the A␤ 2 peptide, which is generated from APP by consecutive proteolytic cleavages mediated by the ␤-and the ␥-secretase. APP is the substrate and PSEN protein is the catalytic subunit of the ␥-secretase, thus AD-causing mutations occur both in the substrate and protease. This is still a major argument for the hypothesis that abnormal A␤ generation is central to the disease process (1) (2) (3) . However, it is important to notice that these mutations do not necessarily exert a purely quantitative effect on A␤ generation. Indeed, only the Swedish double mutation KM670/671NL (4), the recessive A2V mutation (5) , and the putative AD mutation E11K (6) (Fig. 1 ) are known to increase A␤ generation. Other mutations in the C-terminal part of A␤ (amino acids [43] [44] [45] [46] shift the initial ⑀-cut by ␥-secretase from amino acids 50 -51 to amino acids 49 -50 and increase the relative amount of long, more aggregation-prone A␤ fragments versus shorter peptides, without increasing the total amount of A␤ (7) (8) (9) . Other mutations, e.g. at amino acid residues 22-23 near the central hydrophobic domain of A␤ ( Fig. 1) , affect the intramolecular ␤-hairpin formation, thus altering A␤ peptide self-assembly (10, 11) .
Aggregation propensity is an intrinsic property of the A␤ sequence and correlates with the length of the hydrophobic C terminus (12) (13) (14) . Aggregation-prone A␤42 and A␤43 alloforms are usually more neurotoxic than the more abundantly generated A␤40 in different experimental paradigms (14 -17) . A neurotoxic property of A␤ indeed emerges during the initial stages of its aggregation and is associated with the presence of oligomeric A␤ structures (15, 17, 18) . The latter remain the subject of intense investigation (18 -20) . Compelling evidence, however, indicates that such aggregated A␤ peptides can directly affect memory formation, synaptic transmission, and neuron viability (18, 20) .
The central role of APP misprocessing and amyloid generation in the pathogenesis of Alzheimer disease recently received considerable support from the finding of a protective mutation in the APP sequence in a large population-based study (21) . This A673T allele, previously described as a natural APP polymorphism (22) , was investigated in 41 elderly carriers, including three homozygous ones, and these carriers appeared to be protected against AD but also to perform significantly better in cognitive tests compared with a noncarrier population of the same age (21) . These authors provided evidence that the Ala-to-Thr substitution decreased ␤-secretase cleavage of APP and therefore the generation of A␤ peptide with about 40% in a cell line (21) .
A simple interpretation of the data suggests that this mutation provides a life-long and mild suppression (20% in heterozygous carriers) of A␤ generation by BACE-1. Obviously, this would provide a strong argument for the therapeutic development of BACE-1 inhibitors and its preventative use in persons at risk for AD. However, some caution with the interpretation of these data is indicated because little experimental work has been done to evaluate the effect of this mutation on aggregation or neurotoxic properties of the peptide (23) .
Experimental studies of mutations at the N terminus, for instance the so-called English (H6R) and Tottori (D7N) mutations, show an increased oligomerization and/or fibrillogenesis of mutant A␤ peptides (24, 25) . More intriguingly, apart from the protective Ala-to-Thr mutation (21) , an Ala to Val mutation has also been identified in a single Italian kindred with early onset inherited AD. This disease is characterized by both increased A␤ production and increased fibrillogenesis (5, 26) . In vitro studies of the A2V mutant A␤ peptides revealed that they were more toxic than wild type A␤ peptides and also that mixing mutant with wild type (WT) A␤ in an equimolar ratio decreased their toxicity, in line with the protected status of heterozygous carriers of this mutation (5) . Thus, this mutation appears not only to affect the total production but also to have a profound effect on the biophysical and toxic properties of the A␤ peptide, in a way not explained by currently available models for A␤ toxicity.
We therefore set out to investigate the impact of the A2T and A2V mutations on A␤ production but also aggregation. We show that in addition to effects on ␤-cleavage, these mutations profoundly affect aggregation kinetics and the free energy of A␤ aggregation. Furthermore, both mutant peptides interact with wild type A␤ and thermodynamically destabilize its aggregation. These findings provide novel insights into the biophysical parameters that determine aggregation and toxicity of A␤ and reinforce the concept that "quality" of the A␤ mix is more important than absolute amounts of A␤ peptide in the causation of AD.
EXPERIMENTAL PROCEDURES
SFV Expression System and APP Mutagenesis-The plasmid pSFV1-huAPP695 has been described previously (27) . APP mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The following primers were used to introduce the A673T mutation: 5Ј-ctctgaagtgaagatggatacggaattccgacatgactcag-3Ј (forward) and 5Ј-ctgagtcatgtcggaattccgtatccatcttcacttcagag-3Ј (reverse). To introduce the A673V mutation, the following primers were used: 5Ј-ctgaagtgaagatggatgtagaattccgacatgactc-3Ј (forward) and 5Ј-gagtcatgtcggaattctacatccatcttcacttcag-3Ј (reverse). The mutant constructs were transformed into the XL10 gold ultracompetent cells, and a restrictiongrade DNA was isolated. After verification of the mutant sequence using 5Ј-GTCTTGGCCAACATGATTAGTG-3Ј as primer, the APP-expressing and the helper plasmid were transformed into DH5␣ cells. The DNA was isolated, linearized at the SpeI site, purified using the PCR purification kit (Qiagen, catalog no. 28106), eluted in nuclease-free water, and transcribed using the Megascript SP6 kit (catalog no. AM1330M, Ambion/Invitrogen) according to the manufacturer's instructions in the presence of m7G(5Ј)ppp(5Ј)G (catalog no. AM8048, Ambion/Invitrogen). The viral vector was produced in baby hamster kidney cells as described (28) , aliquoted, and stored at Ϫ80°C.
Neuronal Culture Transduction-Primary neuronal cultures were prepared from C57Bl6 mouse brains at embryonic day 14 and plated on 6-cm dishes (Nunc) coated with poly-L-lysine (Sigma), one embryo brain per three dishes. Neurons were seeded in minimal essential medium (Invitrogen, catalog no. 31095-029) supplemented with horse serum, penicillin, and streptomycin (PenStrep, Invitrogen, catalog no. 15140-122). 4 h after plating, medium was replaced with Neurobasal medium (NB, Invitrogen, catalog no. 21103-049) supplemented with B27 (Invitrogen, catalog no. 17504-044), and PenStrep.
Neuronal transduction was performed at in vitro culture day 3. 112 l of viral vector-containing supernatant was added to 1.2 ml of the culture medium for 45 min. Medium was replaced with 1.3 ml of NBϩB27ϩPenStrep as above, and the neuron culture-conditioned medium was collected after 4.5 h. The cells were then washed two times with ice-cold PBS and lysed for 15 min in 300 l of ice-cold radioimmunoprecipitation buffer (150 FIGURE 1. A␤ sequence of amyloid precursor protein. N-terminal part of A␤ fragment (amino acids 1-16) is followed by a central hydrophobic domain (CHD, amino acids 17-21), which is separated from the hydrophobic C-terminal part by a hydrophilic linker (amino acids [22] [23] [24] [25] [26] [27] [28] . Main secretase cleavage sites (␣, ␤, ␤Ј, ␥, and ⑀) are indicated with arrows. Pathogenic N-terminal substitutions in or next to the A␤ sequence are shown in red and include KM670/671NL (Swedish), A2V and H6R (English), and D7N (Tottori). Green, the protective mutation A2T. Black, putative pathogenic mutations E11K and D7H. Familial forms of Alzheimer disease mutation-prone amino acid clusters in central hydrophobic domain and at the C terminus are shown in bold.
mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8) with complete protease inhibitors. The neurons were then scraped and centrifuged at 13,000 rpm for 15 min to remove debris, and the supernatants were snap-frozen and stored at Ϫ80°C until further processing.
Antibodies to APP Fragments-The following antibodies were used: rabbit polyclonal B63 antibody raised against the C terminus of APP (29) ; mouse monoclonal 22C11 antibody recognizing the N terminus of APP and total sAPP, from Chemicon/Biognost; rabbit polyclonal antibody recognizing sAPP␤, from Covance; mouse monoclonal 6E10 antibody recognizing the N-terminal part of the A␤ fragment (amino acids 1-16), from Covance.
Western Blot-Neuronal lysates and supernatants were mixed with 4ϫ sample buffer (450 mM Tris-HCl, pH 8.45, 12% glycerol, 4% SDS, 0.0025% Coomassie Blue, 0.0025% phenol red) plus ␤-mercaptoethanol at a final concentration of 2% and denatured for 15 min at 75°C. 12 l of each sample was loaded on precast 4 -12% Novex BisTris gel and electrophoresed at 125 V, 400 mA for 1.5 h. Proteins were further transferred on 0.2-m nitrocellulose membrane (Protran) at 25 V, 400 mA during 1 h and 40 min. The membrane was blocked in Trisbuffered saline (TBS) with 0.1% Tween 20 and 5% nonfat milk. The primary antibodies were applied overnight at 4°C. Peroxidase-coupled secondary antibodies were applied for 1 h at room temperature. The blots were developed chemiluminescently using enhanced luminol and digitized by means of the ImageQuant LAS4000 mini reader. Quantification of bands was performed in AIDA Image Analyzer version 4.27.
A␤ ELISA-To detect soluble A␤ in neuronal cultures, a sandwich ELISA with end-specific monoclonal antibodies from Janssens Pharmaceutica and generously made available to us by Dr. Mark Mercken was used as described previously (7) . JRFcAb40/28 and JRFcAb42/26 raised against the C terminus of A␤(x-40) and A␤(x-42), respectively, were used as capture antibodies, and JRFAbN/25 recognizing the N-terminal 1-7 amino acids of human A␤ was used as the detection antibody.
96-Well plates (Nunc MaxiSorp) were coated with A␤40 or A␤42 capture antibodies at 1.5 g/ml. After overnight incubation at 4°C, the plates were washed and blocked with casein buffer (0.1% in PBS). Human A␤ standards (A␤40, A␤40-A2T, and A␤40-A2V; A␤42, A␤42-A2T, and A␤42-A2V) in dimethyl sulfoxide (DMSO) were diluted in casein buffer and pre-mixed with the detection antibody at 1:2000. For A␤42 detection, undiluted culture medium samples were used, and a 3ϫ dilution in casein buffer was done for A␤40 detection. Medium mix with the corresponding antibody was added to the coated ELISA plate and incubated overnight at 4°C. The plates were developed using 3,3Ј,5,5Ј-tetramethylbenzidine plus H 2 O 2 (Sigma). The reactions were stopped with 2 N H 2 SO 4 , and absorbance at 450 nm was read on PerkinElmer Life Sciences Envision 2103 multilabel reader. Optical signal versus log A␤ concentration was fitted in GraphPad Prism software with a sigmoid curve with variable slope.
Solubilization of A␤ Peptides-A␤42 variants (wild type, A2T and A2V mutants, and purity Ͼ95% by HPLC/C18) were received from JPT Peptide Technologies GmbH. A␤40 variants (wild type, A2T and A2V mutants, purity Ͼ95% by HPLC/C18) were received from Giotto Bioscience and stored at Ϫ20°C.
Prior to solubilization, the vials containing the peptides were brought to room temperature to avoid formation of condensate and briefly centrifuged to collect powder on the bottom. Peptides were dissolved in 2 ml of hexafluoroisopropanol (1,1,1,3,3,3-hexafluor-2-propanol, or HFIP, 99%, Aldrich catalog no. 10522-8) and briefly sonicated, and HFIP was evaporated under a nitrogen stream. HFIP was added for a second time to obtain a peptide concentration of 1 mg/ml. Mixtures of wild type and mutant (A␤/A␤ mutant) peptides were prepared by mixing the HFIP stock solutions at ratios corresponding to 67, 50, and 33% of mutant peptide.
250 l of HFIP-dissolved A␤ was dried under nitrogen flow to obtain a peptide film that was resolubilized in DMSO (Ͼ99.9%, Sigma catalog no. D41640) to a final peptide concentration of 5 mg/ml, vortexed, and diluted in Tris/EDTA buffer, pH 7.4 (50 mM Tris, 1 mM EDTA), to 100 M peptide. Protein concentration was measured with the protein assay (catalog no. 500-0006, Bio-Rad).
Thioflavin T Fluorescence Assay of Aggregation Kinetics-90 l of freshly solubilized A␤ peptide was loaded on black 96-well plate with a -clear bottom (catalog no. 655096, Greiner Bio One), mixed with 10 l of 0.12 mM aqueous solution of thioflavin T, and sealed with transparent film to prevent evaporation. Aggregation kinetics of A␤ was followed in situ at 25°C using a Fluostar OPTIMA plate reader at ex ϭ 440 nm and em ϭ 480 nm. Gain was set to the 5% of signal intensity in blank probe (unbound dye). Orbital shaking (2 s) was applied before reading every 15 min during Ϸ63 h.
Critical Concentration and Gibbs Energy Evaluation-A series of A␤ peptide samples from 100 to 1.2 M was incubated for 6 weeks in low adhesion plastic vials (catalog no. B74030, Bioplastics) at room temperature. The samples were centrifuged during 3 min at 14,000 rpm at 4°C, and soluble peptide content was assessed by means of the protein assay (Bio-Rad). Insoluble peptide fraction was calculated by subtracting the soluble peptide fraction (C) from the total concentration (C 0 ), and a critical concentration (C c ) was evaluated as described (31) . C c refers to a concentration above which no further increase in soluble peptide is observed and below which there is less than 10% of detectable insoluble material. The Gibbs free energy of aggregation relates to the critical concentration as described under "Results."
Immune Dot Blot-50 M A␤ solutions were aggregated for 2 h, and 3 l were blotted on a nitrocellulose membrane (0.1 m, Protran) and dried. The membrane was blocked in TBS ϩ 0.1% Tween 20 ϩ 5% nonfat milk for 1 h at room temperature, and the primary antibodies were applied at 1:1000 overnight. The following primary antibodies were used: mouse monoclonal antibody 4G8 recognizing a middle region of A␤ (amino acids 18 -22) , from Sigma; mouse monoclonal antibody 3D6 recognizing N terminus of A␤ (amino acids 1-5), from Elan Pharmaceuticals; rabbit polyclonal "conformation-specific" antibody A11 recognizing nonfibrillar oligomers, from Invitrogen; rabbit polyclonal conformation-specific antibody OC recognizing fibrillar oligomers and fibers, from Calbiochem/Millipore. The secondary peroxidase-coupled antibodies were applied for 1 h, and the dot blot was developed in the same way as the Western blots described above.
AFM Analysis of A␤ Oligomers-The 1 ϫ 1 cm silicon/SiO 2 substrates (silicon with 300 nm thermally grown SiO 2 ) were cleaned in Piranha solution (1 volume of H 2 O 2 and 3 volumes of H 2 SO 4 ) for 15 min to make them hydrophilic, then rinsed thoroughly with ultrapure water (UPW, 18.2 megohms), and kept in UPW until use. 40 l of 50 M A␤ sample was deposited on the substrates, dried, then rinsed with UPW, and dried again. The AFM images were obtained in tapping mode in ambient conditions with JPK III AFM (The NanoWizard 3 BioScience AFM) using a silicon tip with an initial radius between 2 and 12 nm on a V shaped nitride cantilever (Brucker, MSNL-10, cantilever F). The nominal spring constant of the cantilever was 0.6 N/m and the frequency used was 120 Ϯ 10 kHz. AFM images were analyzed by means of the WSxM software.
Transmission Electron Microscopy of A␤ Fibers-5 l of aggregated A␤ were adsorbed to carbon-coated Formvar film on 400-mesh copper grids (Laborimpex, S162-4H) for 1 min. The grids were washed five times in UPW and stained with 2% w/v uranyl acetate for 10 s. Samples were then examined with a JEOL JEM-1400 microscope at 80 kV.
Fourier Transform Infrared Spectroscopy-The infrared spectra of aggregated A␤ samples were recorded using a Bruker Tensor 27 infrared spectrophotometer (Bruker Optik GmbH) equipped with a Bio-ATR II accessory. Spectra were recorded at a resolution of 4 cm Ϫ1 , and 128 accumulations were performed per measurement, at a wave number range from 900 to 4000 cm Ϫ1 . UPW was used to record a blank signal. The obtained spectra were vehicle-subtracted and rescaled in the amide I area (from 1600 to 1700 cm Statistical Analysis-Statistical analyses were performed using GraphPad Prism 6 software. One-way analysis of variance with Tukey multiple comparison tests was used to analyze APP processing. Unpaired two-tailed t test was used for analysis of kinetic and thermodynamic parameters of aggregation, ELISAs, and dot blots. Pearson correlation coefficients were used to evaluate correlation between kinetic parameters. Statistical significance of the observations is indicated in the figure legends.
RESULTS

Effects of A2T and A2V Mutation on ␤-Secretase Processing of APP in Neurons-
To confirm and expand previous findings in non-neuronal cell lines (5, 21), we evaluated the effect of the Ala-to-Thr (A673T and A2T) and Ala-to-Val (A673V and A2V) substitutions on APP processing in primary neurons. Site-directed mutagenesis was used to introduce either an A2T or an A2V mutation in the neuronal 695-amino acid-long isoform of human APP, which was then delivered to primary mouse neurons by means of the SFV-based expression system as before (27) . Secreted and membrane-associated products of APP processing were analyzed by means of Western blot ( Fig. 2A and Table 1 ) and sandwich ELISA (Fig. 2, B and C) . In agreement with previous reports (5, 21) , the disease-causative APP A2V mutation induced a robust increase in ␤-cleavage products sAPP␤ and APP-C99 at the cost of ␣-cleavage ( Fig. 2A and Table 1 ). This was accompanied by a significant increase in (695) generated during ␤-, ␤Ј-, and ␥-secretase-mediated cleavage in mouse primary neuronal culture. On the right, C-terminal fragments generated during APP proteolysis, resolved in 16% Tris/Tricine gel, and probed with B63 antibody against the C terminus of APP. C99 is CTF␤; C89 is CTF␤Ј; C83 is CTF␣; and pCTFs are phosphorylated C-terminal fragments. Semi-quantification of band intensities is presented in Table 1 . Note that A673T/A673V refers to the position of mutation in the longest APP isoform (APP(770)), and in APP(695) this corresponds to A598T/A598V and in the A␤ sequence to A2T/A2V. B, calibration curves for ELISA detection of A␤ mutants by using JRFAbN/25 antibody against N-terminal amino acids 1-7 of human A␤, means Ϯ S.D. C, ELISA quantification of soluble A␤40 and A␤42 released by mutant human APP(695)-overexpressing neurons, means ϩ S.E. Statistical significance (unpaired two-tailed t test) is indicated by *, p Ͻ 0.05; **, p Ͻ 0.01; and ***, p Ͻ 0.001; n ϭ 3.
A␤40 and A␤42 secretion (Fig. 2C) . The protective A2T APP mutant in contrast reduced ␤-cleavage significantly, but in contrast to the observations made in non-neuronal cells (21) , no increment in sAPP␣ was observed ( Fig. 2A and Table 1 ). The significant decrease in sAPP␤ (Table 1) was coherent with the 2.3-fold reduction in soluble A␤40 and an almost 3-fold reduction in soluble A␤42 (Fig. 2C) .
Therefore, causative and protective mutations modulate ␤-cleavage in neurons in distinct opposite directions. This confirms in neurons that these mutations affect ␤-secretase cleavage of the APP protein, but the question whether these mutations would also affect aggregation properties of A␤ has not been addressed before. More importantly, we also wondered how these mutant A␤ peptides would interact with their wild type A␤ counterparts as this is directly relevant for the situation in the heterozygote carriers of these mutations.
A2T and A2V Mutations Affect A␤40 Aggregation-We used two independently produced batches of wild type A␤42 and A␤40 and of A␤42 and A␤40 containing either the A2T or the A2V mutations, all with Ͼ95% purity. The peptides were first dissolved in HFIP and then dried under a nitrogen stream and reconstituted in dimethyl sulfoxide (DMSO). DMSO solution was further diluted with Tris/EDTA buffer, pH 7.4, to reach a final concentration of peptide of 25 M. The aggregation of A␤ peptides was followed using the ␤-sheet-sensitive fluorescent dye thioflavin T (ThT).
The A2V and A2T mutants either as a pure mixture or as a 1:1 mixture with wild type A␤42 followed the similar fast aggregation course as pure wild type A␤42 peptide, without a discernible lag phase (Fig. 3A) suggesting that nucleation of all A␤42 samples occurred during the dead time of the experiment (Յ30 min) (Fig. 3A) .
The A␤40 peptide is intrinsically less aggregation-prone. In the context of A␤40, a remarkable impact of the A2T and A2V mutations on aggregation became apparent. A␤40-A2V on the one hand aggregated without a lag phase following a pattern that is more like wild type A␤42 than A␤40, and on the other hand, A␤40-A2T showed a 1.5-fold increase in lag phase (Fig.  3B) . Of note, the kinetic curves of the equimolar mixes of A␤40 with the mutant variants represented an average between the wild type and the pure mutant suggesting little interaction of wild type and mutant A␤ in these mixes.
A2T and A2V Mutations Affect Kinetic Parameters of A␤40 Aggregation-We next determined how the nucleation (t lag ) and the fiber growth rate (k) are affected by changes in the initial peptide concentration. The rate of aggregation (k) was obtained by fitting a single exponential function to the growth phase of the aggregation curve, and lag time (t lag ) was determined as the intersection of the linear part of the initial growth phase with the baseline (Fig. 4A) (32) . A series of dilutions from 100 to 1.2 M was prepared from A␤40 ( Fig. 4B) , and its mutant variants (Fig. 4, C and D) and kinetic curves were obtained using the ThT incorporation assay.
Increasing the peptide concentration typically leads to an acceleration of the elongation rate (k) and a shortening of the lag time (t lag ). Because k and t lag are governed by similar physicochemical interactions, usually a (negative) correlation between k and t lag is observed for almost any peptide tested (33) . Interestingly, the A2T mutant deviated from that rule (Fig. 4F) , although the anti-correlation was observed for the wild type A␤40 (Fig. 4E ) and for A␤40-A2V (Fig. 4G) . The A2V mutation increases k dramatically, whereas t lag becomes shorter with increasing concentrations and is shorter compared with wild type (Fig. 4G) . Conversely, the elongation rate for the A2T mutant is similar as for the wild type, but the t lag of the A2T mutant does not change much with increasing concentrations (Fig. 4F) . At 100 M, however, the aggregation kinetics of the A2T mutant becomes biphasic resembling the lag-free aggregation of the A2V mutant (Fig. 4G) . The first plateau of the A2T aggregation curve includes only 19 Ϯ 0.6% (n ϭ 3) of the second plateau height and thus is three times less pronounced as compared with the A2V curve (63 Ϯ 11%, n ϭ 3). 
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We next wondered how mixtures of A␤/A␤-A2T would behave in this assay. Increasing A␤-A2T in the A␤/A␤-A2T mixes revealed a small gradual increase in t lag (Fig. 5, A and B) , although at 100 M, the aggregation became biphasic and lagfree. However, the disease-causing A␤-A2V inhibits nucleation when present at low amounts (33%, Fig. 5, C and D) , but the presence of 50% or more of A2V in the mix led to a strong decrease of the lag phase (Fig. 5, C and D) . The data thus implicate a concentration-dependent inhibitory effect of the protective A2T mutant and a complex behavior of the disease-causing A2V mutant on the nucleation propensity of wild type A␤40.
Effect of A2T and A2V Mutations on A␤ OligomerizationWe next asked whether differently aggregating A2T and A2V mutants form different oligomers, using both A␤42 and A␤40 peptides. The number of analytical tools to study such oligomers is limited, but AFM allows visualizing such species to a certain extent. We focused on early aggregates formed by the mutants and their equimolar mixtures with the WT A␤42 and A␤40 peptides, and we found a broad range of amorphous structures after 2 h of incubation (Fig. 6, A and D) . All A␤42 preparations formed larger aggregates compared with A␤40, and mutant preparations formed smaller structures than corresponding wild type peptides. The A2T mutants and their mixes with WT A␤40 and A␤42 formed the smallest aggregates in all preparations, probably indicative of impaired nucleation, as observed in the kinetic assay (Fig. 4, C and F) .
We also made use of conformation-sensitive polyclonal antibodies; A11 and OC claimed to recognize nonfibrillar and fibrillar aggregates, respectively (34) . A11 reactivity of oligomeric species is often regarded as a correlate of their toxic potencies (35, 36) . Wild type A␤42 and to a smaller extent A␤40 peptide pre-aggregated for 2 h showed strong A11-and OCpositive staining (Fig. 6, B and E) , implicating the co-existence of both the nonfibrillar and fibrillar oligomers in these preparations. Interestingly, both the A2T and A2V mutants of A␤42 and A␤40 were consistently A11-and OC-negative suggesting the involvement of the N terminus of these peptides in the formation of the tertiary structure recognized by these conformation-specific antibodies (Fig. 6, B and E) . The equimolar mixes of WT peptides with either A2T or A2V variants were A11-and OC-positive, although the A11 signal was rather proportional to the amount of WT peptide in these samples.
We next probed the hydrophobic exposure of the putative oligomers using ANS binding assay (Fig. 6 , C and F, and Table  2 ), considered to be another correlate to the toxic properties of oligomers (37, 38) . In this assay, the fluorescence of ANS increases upon binding to the lipophilic entities, and the emission maximum undergoes a blue shift. The mixes of A2T and A2V with the wild type A␤42 and A␤40 demonstrated a lower magnitude and a slight red shift of ANS spectra compared with the WT and mutant peptide spectra (Fig. 6 , C and F, and Table  2 ). Thus, both protective and causative mutants affect tertiary structure of the early aggregates, resulting in decreased exposed hydrophobic surface of both A2T and A2V variants.
Effect of A2T and A2V Mutations on A␤ Fiber Structure-We next investigated how the two different mutations affected 
and 3.7 M. E-G, correlation between kinetic parameters of wild type A␤40 (E), A␤40-A2T (F), and A␤40-A2V (G).
Note that A2T mutation disrupts the inverse correlation between k and t lag. Significance of correlation was evaluated from the Pearson coefficients shown on the plots and is indicated by **, p Ͻ 0.01, means Ϯ S.E., n ϭ 3. fibril formation. A␤40 and A␤42 mixtures were aggregated for 2 weeks, and their secondary structure was analyzed by means of FTIR (Fig. 7) . Both A␤42 and A␤40 peptides showed a strong enrichment for ␤-sheet structure (peak at 1627 cm Ϫ1 , Fig. 7 , A and C, in line with previous observations (39, 40) ). The mixtures of the wild type A␤42 with A2T and A2V mutants were structurally different from the pure A␤42 peptides. Additional absorbance was observed between 1657 and 1665 cm Ϫ1 indicative of unstructured or helical components, in addition to the ␤-sheet content (Fig. 7B) . A␤40 mutants and A␤40-based mixtures were all enriched in ␤-sheet structures (Fig. 7, C and D) .
We also analyzed the aggregated material using transmission electron microscopy. A␤42-A2T and A␤42-A2V fibers were cooccurring with amorphous aggregates in contrast to the net fibers of WT A␤42 (Fig. 8A ) and did not undergo further structural change after prolonged incubation (data not shown). The A␤40 containing material formed predominantly amorphous aggregates after 2 weeks of incubation (Fig. 8C ) that converted into mature fibers after 6 weeks of incubation (Fig. 8D ). A␤42 and A␤40 variants became 85-90% insoluble after a few weeks of incubation except the A2T mutants, which still contained twice as much soluble peptide as the wild type and A2V mutants (Fig. 8, B and E) .
Immune reactivity of both A␤42 and A␤40 fibers with A11 or OC antibodies (Fig. 8F) was similar to what was observed with the shorter incubations of A␤42 and A␤40 (Fig. 6, B and E) ; the mutant fibers were not reactive with the OC antibody; the A11 reactivity in the fibrillar wild type peptides was negligible. Interestingly, the accessibility of N termini in aggregated samples did not change as staining with the N-terminal 3D6 antibody was maintained (Fig. 8F) .
Effects on Gibbs Free Energy of Aggregation-The Gibbs free energy of aggregation relates to the critical concentration and can be calculated by Equation 1,
where R is the gas constant (R ϭ 8.314 J/mol⅐K); T represents the absolute temperature, and C c is the critical concentration of the peptide (31) . All calculations were done for T ϭ 298 K.
We thus first evaluated the critical concentrations of A␤40 and mutant A␤40 (Fig. 9A) . A series of peptide dilutions from 100 to 1.2 M was incubated for 6 weeks at room temperature, and the residual soluble peptide was monitored after 1, 3, and 6 weeks (Fig. 9A) . The critical concentrations (Fig. 9A) were determined as described (31) after 6 weeks of incubation. Interestingly, the solubility of the A2V mutant drops faster as compared with the wild type A␤40 (Fig. 9A) , in line with kinetic data, but then further precipitation slows down, which results in comparable critical concentrations with WT peptide (Fig.  9A ). These were used to calculate Gibbs free energy of aggregation (⌬G) using Equation 1, above (Fig. 9B) . ⌬G value provides a thermodynamic quantification for the tendency of the peptide mixture to populate the amyloid state, i.e. the lower ⌬G, the NOVEMBER 7, 2014 • VOLUME 289 • NUMBER 45 more favorable the amyloid state. In good agreement with previous work (31), we found a ⌬G for WT A␤40 of Ϫ7 Ϯ 0.23 kcal/mol, although under the same conditions the ⌬G of A2T was significantly higher (⌬G ϭ Ϫ6.29 Ϯ 0.18 kcal/mol). The ⌬G of A2V was within error the same (⌬G ϭ Ϫ6.89 Ϯ 0.13 kcal/ mol) as the wild type A␤40.
Effect of Protective Mutation on A␤ Aggregation
We next assessed the impact of the A2T and A2V mutant on Gibbs energy of A␤40 aggregation in a series of mixes (Table 3 and Fig. 9C ). The changes in the Gibbs free energy (⌬⌬G) in the mixtures of A␤40 with either A2T or A2V mutants were calculated using the equation ⌬⌬G ϭ ⌬G(X) Ϫ ⌬G(Ala), where X is the A2T or A2V mutant present in a given mixture. As can be FIGURE 6. Effect of the A2T and A2V mutations on morphology, immune reactivity, and hydrophobic exposure of A␤42 and A␤40 oligomers. A, atomic force micrographs of pre-aggregated A␤42 mutants and their equimolar mixes with the wild type A␤42. Images are obtained in the tapping mode under ambient conditions. On the right, A␤42 oligomer size histograms obtained via the multiple Gaussian distribution fit of particle height. The peak height is 3.1 nm for WT A␤42, 2.49 nm for A␤40-A2T, 2.76 nm for A␤40-A2V, 2.72 nm for A␤40/A␤40-A2T, and 2.9 nm for A␤40/A␤40-A2V. B, immune dot blot of A␤42. A␤ was incubated in Tris/EDTA buffer, pH 7.4, for 2 h, blotted on a nitrocellulose membrane, and probed with conformation-specific antibodies A11 and OC. 4G8 antibody, which reacts with all A␤ forms, was used as a loading control. Right panel, densitometric analysis of A␤42 dot blots. A11 and OC reactivity of mutant aggregates are significantly diminished compared with WT aggregates (unpaired two-tailed t test; *, p Ͻ 0.05; ***, p Ͻ 0.001; ****, p Ͻ 0.0001, meansϩ S.E., n ϭ 4). C, normalized fluorescent spectra of 8-anilinonaphthalene-1-sulfonate (ANS) dye upon its binding to pre-aggregated A␤42 mutants and their 1:1 mixes with the wild type peptide. A mean value from n ϭ 2 in duplicate is plotted. Increased magnitude and blue shifting of ANS spectra are indicative of increased hydrophobicity of the ANS-bound entities. D, atomic force micrographs of pre-aggregated A␤40 mutants and their equimolar mixes with the wild type A␤40. Images are obtained in the tapping mode under ambient conditions. On the right: A␤40 oligomer size histograms obtained via the multiple Gaussian distribution fit of particle height. The peak height is as follows: 2.87 nm for WT A␤40, 2.38 nm for A␤40-A2T, 2.43 nm for A␤40-A2V, 2.19 nm for A␤40/A␤40-A2T, and 2.47 nm for A␤40/A␤40-A2V. E, immune dot blot of A␤40. A␤ was incubated in Tris/EDTA buffer, pH 7.4, for 2 h, blotted on a nitrocellulose membrane, and probed with A11 and OC antibodies. 4G8 antibody was used as a loading control. Right panel: densitometric analysis of A␤40 dot blots. A11 and OC reactivities of mutant aggregates are significantly diminished compared with WT aggregates (unpaired two-tailed t test; *, p Ͻ 0.05; ***, p Ͻ 0.001; ****, p Ͻ 0.0001, means ϩ S.E., n ϭ 4). F, normalized fluorescent spectra of the ANS dye upon its binding to pre-aggregated A␤40 mutants and their 1:1 mixes with the wild type peptide. A mean value from n ϭ 2 in duplicate is plotted. veh, vehicle; a.u., arbitrary units; Wavel, wave length.
seen from the positive increments in Gibbs energy ⌬⌬G conferred to the WT by the presence of the A2T or A2V mutant (Fig. 9C) , both A2T and A2V mutant peptides solubilize WT A␤40. A2T does this to a greater extent than A2V. When A2V mutant constituted 33% of the mix, both aggregation kinetics as well as amyloid stability decreased (Figs. 5, C and D, and 9C ). For A2T, the difference in lag phase duration between mixes was less dramatic (Fig. 5, A and B) , and ⌬⌬G values for all the mixes were comparably high, around 0.7-0.9 kcal/mol, indicating a strong destabilizing effect of A2T on A␤40 aggregation. Changes in Gibbs energy thus followed the change in the nucleation phase of aggregation, in line with the literature (31).
DISCUSSION
The A2V and the A2T mutations in the APP sequence are intriguing as they have opposing effects on the risk to develop Alzheimer disease (5, 21) . We confirm here that these mutations close to the ␤-secretase cleavage site in APP have indeed opposite effects on the proteolytic processing of APP toward A␤ peptides. This reinforces the amyloid hypothesis of AD, which suggests that abnormal amyloid generation is a triggering, initiating, or driving event in the disease cascade (1). The first conclusion of our work is, however, that the A2T mutation has a profound effect on a series of biophysical parameters of A␤ peptide aggregation. Thus, the effects of the protective A2T mutant with regard to AD pathobiology are not only quantitative (21) but also qualitative as suggested before (23) . In fact, the A2V mutation exerts also complex interactions with the wild type peptide explaining why it is only disease-causing in the homozygous situation (5) .
To compare the effects of the protective and causative mutations on A␤ peptide aggregation, we performed detailed kinetic analysis of A␤ self-assembly, and we also compared the behavior of the peptides at equilibrium. Interestingly, although the effects of the N-terminal mutations on the kinetic parameters measured for aggregation were masked by the high aggregation propensity of the A␤42 peptide (Fig. 3A) , the onset of dynamic equilibrium was differentially affected in A␤42-A2T and A␤42-A2V peptides (Fig. 8B ). These observations are in line with the Effect of Protective Mutation on A␤ Aggregation NOVEMBER 7, 2014 • VOLUME 289 • NUMBER 45
proposed critical role of the C terminus in the kinetics of amyloid formation and its minor role in A␤ peptide solubility at equilibrium (13) . Study of the less hydrophobic and less aggregation-prone A␤40 peptide, however, revealed not only the increased residual solubility of A2T (Fig. 8E ) but also the delayed aggregation of the A2T mutant and enhanced aggregation of the A2V mutant when above the critical concentrations (Figs. 3B, 4 , and 9A). Because nucleation time (t lag ) inversely correlates with sequence hydrophobicity (41), the kinetic effect of the protective mutation on A␤40 aggregation could originate from the subtle changes in hydrophobicity conferred by the polar threonine. This is congruent with the ANS binding data showing a reduced hydrophobicity of A␤40-A2T aggregates (Fig. 6F, left panel) . A delayed onset of elongation and increased residual solubility conferred by the A2T mutation are indicative of less productive interactions between the monomers and/or the larger building blocks above the critical concentrations. This is in line with the AFM data revealing the presence of small aggregates in A2T mutants pre-aggregated for 2 h (Fig. 6, A  and D) . Experimental evidence suggests that readily aggregating sequences have lower critical concentrations; in other words, kinetic and thermodynamic aspects of aggregation are governed by the same physicochemical mechanisms (31) , and this holds for A␤ mutations at different positions (41) . In case of the A2V mutation, the relation between the speed and the energy of aggregation appears more complex. On the one hand, the accelerated kinetics (Figs. 3B and 4D) , reminiscent of A␤42 (Fig. 3A) , pointed to a very efficient self-assembly, possibly fostered by interactions between the more hydrophobic A2V mutant N-terminal tails. On the other hand, at concentrations significantly exceeding the critical one (8.5 Ϯ 0.9 M), these interactions become less productive. Alternatively, a structural re-arrangement of aggregation nuclei occurs leading to an intermediate plateau stage during elongation that can be regarded as another lag phase (Fig. 4D) . This rate-limiting process may explain why the Gibbs aggregation energy of A␤40-A2V was, at the end, not lower than the energy of the wild type sequence (Fig. 9A) .
Hortschansky et al. (31) compared changes in Gibbs energy conferred by substitution of residue 18 of A␤40 with different amino acids. Of particular interest, substitution of Gly-18 with threonine caused a 0.11 kcal/mol increase of the Gibbs aggregation energy of A␤ peptide as compared with a thermodynam- Significance (unpaired two-tailed t test) is indicated by *, p Ͻ 0.05, means ϩ S.E., n ϭ 3. C, transmission electron micrographs of the fibers formed by A␤40 variants and their equimolar mixes with the wild type A␤40 after 2 weeks and 6 weeks (D) of quiescent incubation. E, residual soluble peptide content in A␤40 mutants incubated at 100 M for 6 weeks. Significance (unpaired two-tailed t test) is indicated by *, p Ͻ 0.05, means ϩ S.E., n ϭ 3. F, immune dot blot of A␤42 fibers. A␤ was incubated in Tris/EDTA buffer, pH 7.4, for 2 weeks, blotted on a nitrocellulose membrane, and probed with conformation-specific antibodies A11 and OC. 4G8 antibody was used as a loading control. 3D6 antibody recognizing the first five amino acids of A␤ was used to probe N-terminal accessibility in mutant aggregates. Immune reactivity of A␤40 fibers did not change between 2 and 6 weeks of aggregation and was identical to the one of A␤42. Right panel: densitometric analysis of A␤ fiber dot blots. OC reactivity of the mutant fibers is significantly diminished compared with the WT fibers (unpaired two-tailed t test; **, p Ͻ 0.01, means ϩ S.E., n ϭ 3-4). A11 signal intensities of fibers can be considered negligible.
ically more favorable glycine-to-valine substitution (G18V) that diminished the aggregation energy of A␤40 by Ϫ0.03 kcal/ mol. The magnitude of changes in ⌬G between A2T and A2V mutants is larger than the difference between G18T and G18V energies suggesting a surprisingly pronounced effect of N-terminal mutations on fibrillization. Alternatively, small differences in methodology used to measure the critical concentrations should be considered. Additional evidence for the important effects of the N-terminal mutations on A␤ aggregation is the delayed onset of mutant fiber formation. The residual solubility of A␤40-A2V decreases already after 1 week (Fig. 9A) ; however, the A2V mutants similarly to A2T form mature fibers only after prolonged incubation (Fig. 8, C and D) . The transition of heterogeneous aggregates formed after 2 weeks of incubation (Fig. 8C) to a more mature structure (Fig. 8D) is delayed due to the kinetic and/or thermodynamic barriers that govern the aggregation of the mutant A␤40.
It is true that the N terminus of the A␤ fragment does not take part in the amyloid fiber core formation and is usually regarded as unstructured. Recent crystallization studies brought forward an ␣-helical conformation of A␤'s N terminus in complex with the 3D6-based therapeutic antibody bapineuzumab (42) . Experimental evidence nevertheless suggests that N-terminal substitutions can affect A␤ aggregation (5, 24, 25, 43) . For instance, before being identified in the clinic, the A2V mutation itself was isolated as an aggregation-prone variant by screening mutant A␤40-GFP fusions in Escherichia coli (44) .
The second important conclusion from our work is that mixtures of A␤ peptides behave in a complex way. This is particularly relevant if one considers that in reality A␤ peptides are always heterogeneous, affecting their ultimate biophysical behaviors in various ways (14, 15, 20) . In the mixtures of the wild type A␤40 with the A2T mutant, the lag phase extended proportionally to the increase of A2T mutant in the mixture (Fig. 5, A and B) , although these changes were overall modest. At the highest tested concentration (100 M), the aggregation kinetics of pure A␤40 was altered resembling the one of A␤40-A2V, but this effect was not present at lower concentrations of the mutant (Fig. 4, C and D) .
Changes in the Gibbs aggregation energy were comparably high in all A2T mixtures indicating a strong destabilizing effect of A␤40-A2T on A␤40 aggregation (Fig. 9C and Table 3 ). This was reflected in the lower hydrophobic exposure of A␤/A␤-A2T mixes (for both A␤42 and A␤40, Fig. 6, C and F, left panel) and in the presence of very small aggregates during the first few hours of aggregation (Fig. 6, A and D) . FTIR spectra revealed Table 3 .
TABLE 3
Changes of Gibbs free energy of A␤40 aggregation upon the titration of the wild type A␤40 with mutant (A2X) peptides ⌬G is determined as described under "Experimental Procedures" and presented as means Ϯ S.D., n ϭ 3.
A2X ؉ WT A␤40
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non-␤-sheet structures in A␤42/A␤42-A2T peptide mixtures supporting a destabilizing effect of the A2T mutation on amyloid fiber formation (Fig. 7B ).
In the mixtures of the wild type A␤40 with the A2V mutant, the lag phase duration inversely correlated with the amount of A2V mutant (Fig. 5C ) and was coherent with the gradual decrease of the aggregation energy (Fig. 9B) . The alanine-tovaline substitution was also thermodynamically destabilizing as judged from the positive increment in ⌬G (Fig. 9C) , and lower hydrophobic exposure of A␤/A␤-A2V mixes (Fig. 6, C and F,  right panel) was observed.
Decreased aggregation propensity of A2T mutants and heterozygous mixtures of A2T/V with the wild type peptide render them more available for degradation. This is in line with the absence of cerebral amyloidosis in A2T carriers even at advanced age (45) and with the protected status of heterozygous carriers of A2V (5) . These effects of A2T and A2V mutations on peptide aggregation are striking; however, the interpretation of A␤ aggregation studies in the context of any clinical phenotypes should take into account other aspects of A␤ and APP biology. A recent study (46) showed that A2T and A2V mutations rendered WT APP incapable of mediating TGF␤2-induced cell death. Moreover, the flexible N-terminal part of the A␤ fragment itself may be important for interaction with some "toxic A␤ receptors," e.g. FcybII (30) , and thus, N-terminal mutations in A␤ may affect receptor-driven synaptotoxic cascades. Furthermore, the changes in full-length A␤ production caused by the A2T and A2V mutations might also affect more indirectly the toxic or aggregation behaviors of the resulting A␤ mixes. Of note, non-neuronal cells expressing the A2V mutation showed an increased secretion of N-truncated species A␤ , A␤ , and A␤N3pE-42 (5). It will be interesting to check whether A2T and A2V mutations affect the N-terminal truncated species generation in patients as well.
In conclusion, the complex effects of the A2T mutation link this mutation to various aspects of A␤ biophysics. The simple conclusion that the chronic and mild lowering of the amount of A␤ produced over a lifetime explains that the protective effect of this mutant against AD has therefore to be considered with sufficient caution (23) . Reduced A␤ production by A2T mutants should not be considered as the "ultimate" argument in favor for BACE1 drug development as the effects of this mutation cannot only be explained in quantitative terms. We have previously already shown that A␤ pathobiology is not only driven by quantity but that A␤ peptide behavior is also strongly modulated by the quality and relative composition of the A␤ profile in a mixture (15) . Basically any subtle alterations in the biophysical properties of the A␤ peptide can have major effects at the level of seeding and aggregation. The complexity of these processes should not be ignored when contemplating approaches to cure or prevent AD.
